Ryan & Maniskas, LLP is investigating whether the directors of Dialysis Corporation of America, Inc. ("Dialysis" or the “Company”) (NASDAQ:DCAI) breached their fiduciary duties in approving the proposed merger of the Company with U.S. Renal Care, Inc. (“USRC”). USRC, through a subsidiary, will commence a tender offer for all of the outstanding common shares of DCA for $11.25 per share in cash, followed by a merger to acquire all remaining outstanding DCA shares at the same cash price paid in the tender offer. The investigation concerns possible breaches of fiduciary duty and other violations of law related to approval of the transaction by Company’s board of directors.

If you own shares of Dialysis and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, visit: www.rmclasslaw.com/cases/dialysis, or contact Richard A. Maniskas, Esquire toll-free: (877) 316-3218, or by e-mail: rmaniskas@rmclasslaw.com. For more information about class action cases in general, please visit our website: www.rmclasslaw.com.

Dialysis OF America (NASDAQ:DCAI)
Historical Stock Chart
Von Mär 2025 bis Apr 2025 Click Here for more Dialysis OF America Charts.
Dialysis OF America (NASDAQ:DCAI)
Historical Stock Chart
Von Apr 2024 bis Apr 2025 Click Here for more Dialysis OF America Charts.